Nilsine Partners LLC Purchases 600 Shares of Eli Lilly and Company (NYSE:LLY)

Nilsine Partners LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,916 shares of the company's stock after acquiring an additional 600 shares during the period. Eli Lilly and Company accounts for 1.0% of Nilsine Partners LLC's portfolio, making the stock its 19th largest position. Nilsine Partners LLC's holdings in Eli Lilly and Company were worth $9,199,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Algert Global LLC raised its stake in Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company's stock worth $456,000 after buying an additional 110 shares during the period. Granite Bay Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $323,000. RiverFront Investment Group LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $256,000. Strategic Investment Solutions Inc. IL acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $565,000. Finally, Clear Rock Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at approximately $229,000. Institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Redburn Atlantic raised Eli Lilly and Company to a "hold" rating in a research note on Monday, November 4th. Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price target on the stock. Wells Fargo & Company reduced their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating for the company in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a report on Monday, November 4th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $997.22.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $19.51 during midday trading on Thursday, hitting $823.59. 2,641,691 shares of the company traded hands, compared to its average volume of 3,922,107. The stock has a market cap of $781.85 billion, a price-to-earnings ratio of 89.04, a PEG ratio of 1.59 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm's fifty day moving average price is $780.80 and its 200-day moving average price is $845.98. Eli Lilly and Company has a 12 month low of $637.00 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm's revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company announced that its board has authorized a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.